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Abstract
Introduction Neurofibromatosis type 2 (NF2) is an
inherited, rare autosomal dominant syndrome characterised
by the development of multiple benign cranial and spinal
tumours, peripheral neuropathy, ophthalmological and
cutaneous lesions. Herein, we report one case of NF2
treated with multivariate chemotherapy.
Material and methods A 13-year-old female presented with
multiple cranio-spinal tumours in MRI. First symptoms
were progressive changes in vision, left-sided paresis,
unilateral sensorineural hearing loss, and left hypoglossal
nerve paresis. The patient underwent palliative, partial
surgical resection of the tumour which was located in a
posterior fossa. Histopathological examination showed a
psammomatous meningioma located near the great foramen
and schwannomas of VIII nerve in the cerebello-pontine
angle. Clinical and radiological examination revealed a
rapid progression of the disease. As such, multivariate
chemotherapy was used. The patient died 4 years after
diagnosis.
Conclusion NF2 patients with multiple tumours at diagnosis
may not be treatable with surgery alone and, as a result,
presentation with such a disease in childhood results in poor
prognosis. The unification of management strategies in NF2
patients is highly desirable.
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Introduction
Neurofibromatosis type 2 (NF2) is an inherited, rare autoso-
mal dominant syndrome characterized by the development of
multiple benign cranial and spinal tumours (schwannomas,
meningiomas, ependymomas), peripheral neuropathy, oph-
thalmological and cutaneous lesions [1–3]. Tumours associ-
ated with NF2 are caused by the inactivation of both alleles
of the NF2 tumour-suppressor gene that has been localised
on the chromosome 22q12, by mutation or allele loss [1–5].
Recent evidence suggests that between 20% and 30% of
NF2 cases without a family history of the disease are mosaic
for the underlying disease-causing mutation and more than
50% of patients represent new mutations [4]. The disorder
appears in one of 25,000 live births [1]. About 10% of NF2
patients are under the age of 10 years old. Among patients
with NF2, 18% present with symptoms of the disease at the
age of 15 years or less [6]. Although most tumours in the
central nervous system in NF2 are slow growing, they may
grow faster during childhood. In this situation, the prognosis
is often poor [7]. The development of new tumours is likely
in patients with NF2, even after surgery [4, 5]. In these
situations, a new management strategy and early diagnosis
are necessary.
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female with NF2 who had multiple types of primary
tumours in the brain and spinal canal.
Case report
A 13-year-old female was admitted to the Department of
Paediatric Oncology because of complaints of progressive
changes in vision, left-sided paresis, unilateral sensorineural
hearing loss, left hypoglossal nerve paresis and difficulties
in learning at school over a period of 6 months. The
physical examination showed one café-au-lait spot on the
left upper leg (greater than 10 cm in diameter) and one on
the left scapula, schwannomas of the forearms and
dysmorfic face (depressed nasal root, hypertelorism, small
and downward slanting palpebral fissures, short philtrum
with a tented upper lip and mandibular hypoplasia).
Neurological examination revealed bilateral Babinski's
reflex, left-sided muscular atrophy and a deflection of the
tongue to the left. Magnetic resonance imaging (MRI) of
the brain and spinal canal revealed multiple cranial nerves
tumours: V-trigeminal nerve, bilateral vestibular schwanno-
mas and right-sided meningioma, and meningioma in the
area of the optic nerve (Fig. 1a, b). In the posterior cranial
fossa, the huge focus involving the foramen magnum was
described as schwannomas of VIII nerve (Fig. 2). Multiple
spinal canal nodules, involving L5-S1 level, were observed
(Fig. 3). The patient underwent palliative, partial surgical
resection of the posterior fossa tumour. Histopathological
examination showed psammomatous meningioma localised
near the foramen magnum and schwannoma in the
cerebello-pontine angle.
Following the operation, an increased paresis of lower
limbs and neurogenic bladder was observed. The excision
of the Th11-Th12 tumour was performed. Histopathology
proved meningioma. Staphylococcus sepsis and acute renal
failure were the side effects after surgery.
She finished the treatment with clinical success.
Fourteen months later, progression of the disease was
stated. Bilateral deafness, facial nerve paresis, a deflection
of the tongue to the right, left eye-ball oedema, visual
disorders and ape hand were all observed.
She received chemotherapy (vinblastin 6 mg/m
2 every
2 weeks for 3 months). In the course of performing MRI of
the brain and spinal canal, progression of the disease was
observed. The general condition of the patient deteriorated.
She was presented with difficulties in talking and severe co-
ordination disturbances; she was unable to walk in a straight
line and had lost the ability to manipulate small objects. The
chemotherapy for low-grade gliomas protocol, according to
the Memorial Hospital for Children in Warsaw, was
administered thereafter. It was comprised of: intensive
chemotherapy–carboplatin (550 mg/m
2;1 ,4 ,7 ,1 0w e e k s ) ,
vincristin (1.5 mg/m
2,1 –10 week) and maintenance chemo-
therapy–carboplatin with vincristin every 4 weeks.
After 6 months, no response to chemotherapy was stated.
Due to nopossibility toremovethe tumourradically, the child
was included in a clinical trial. She received Irinotecan in
doses of 20 mg/m
2 for 10 days every 3 weeks. In all, nine
cycles were administered to the patient. Thanks to Irinote-
can, she achieved the clinical stagnation of the disease.
Following a period of 2 years, progression of the disease
was once more present. She was treated with temozolomide
(150 mg/m
2) for 3 months. Finally, our patient died of the
progression of the disease 4 years after diagnosis.
Discussion
NF2 is an uncommon genetic disorder, which is character-
ized by an increased risk of benign nervous system tumour
development [8]. The diagnostic criteria for neurofibroma-
tosis type 2 is bilateral vestibular schwannomas (VS) or
family history of NF2 according to first degree family
relative, unilateral vestbular schwannomas under 30 years
old, or any two of the following: meningioma, glioma,
schwannoma, juvenile posterior subcapsular lenticular
opacities/juvenile cortical cataract [9–12]. Nunes et al.
[13], presented clinical data on 12 patients with NF2 at
age before 18 years and in large number with positive
family history. One third of the children had hearing
impairments and two thirds presented with dysfunctions
of the cranial nerve. Radiological examinations revealed
cranial meningiomas in 75% of cases, cranial schwannoms
in 83%, and spinal cord tumours in 75%. Evans et al. [14]
showed that at least 18% of NF2 sufferers presented in
childhood with isolated features of the disease had no
family history. These paediatric patients presented with a
more severe course of the disease with multiple tumours. In
the study of Bosch et al. [15], children with early onset of
the disease presented with ophthalmologic symptoms and
lower motor neuron extremity weakness and in those with
late disease onset, eight nerve impairment was observed.
MacCollin and Mautner [16] showed that the first ocular
manifestation of NF2 in the paediatric population was
visual loss or diplopia. Our patient had an atypical onset of
this autosomal-dominant disorder. After a few months, she
presented with hearing loss, most often related to the
development of vestibular schwannomas. Hearing loss,
often accompanied by tinnitus, occurs in around 60% of
adults and up to 30% of children [17, 18]. The MRI scan
showed the presence of tumours in the central nervous
system and spinal canal. In the literature, there are a great
many reports confirming the variety of spinal tumours
associated with NF2 [2, 19, 20]. Bilateral vestibular
176 Childs Nerv Syst (2011) 27:175–178schwannomas are found in 90–95% of patients with NF2. It
is reported that more than 99% of VS in NF2 are benign,
but they remain an important cause of mortality due to their
location [1]. Schwannomas can develop along the course of
cranial, spinal and peripheral nerves, differently than
vestibular. Most often it arises from the oculomotor,
trigeminal and facial nerves [21]. Schwannomas of spinal
nerves may result in discrete peripheral neuropathies. In our
patient, the histopathology examination showed meningio-
ma in the posterior cranial fossa, which is the second most
common tumour connected with NF2. Intracranial menin-
giomas appear in 45–58% of patients with this disorder and
intradural extramedullary spinal meningiomas in 20% [2].
Although meningiomas are benign, they may give clinical
symptoms, the nature of which are related to their size and
anatomical location. It is proven that meningiomas associ-
Fig. 3 Contrast-enhanced T1-weighted MR image: numerous intra-
dural spinal canal nodules and small tumours in intervertebral foramen
on the right side at level L5-S1
Fig. 2 In the posterior cranial fossa, bilateral pathological solid
masses located in pontocerebellar cisterns, which extend to the
auditory meatus; intensive contrast enhancement MR image—
schwannomas of the VIII nerve
Fig. 1 a Contrast-enhanced
conventional T1-weighted MR
image: neuromas of the V and
VIII nerve and sagittal
right-sided meningioma.
b Contrast-enhanced transversal
T1-weighted MR image: the
optic nerve glioma
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activity and a tendency to form more atypical and
anaplastic grades than sporadic meningiomas [22].
The typical treatment strategy for patients with VS is
“watch and wait then rescan”, complete with surgical
resection and stereotactic radiotherapy. The authors noted
that more than 50% of VS were stable in size, so in this
situation the “watch and wait then rescan” program could
be deemed the proper course [7]. Of contrary opinion is
Brackmann et al. [23], regarding situations in which
tumours are of less than 3 cm in diameter when early
surgical management is recommended. It can preserve
normal hearing in 30–65% and the functioning of facial
nerves in 75–92% of patients. The role of stereotactic
radiotherapy is not yet clearly determined [7].
The majority of meningiomas located in hemispheres and
spinal canal canberesectedsafelyand radically. In ourpatient,
the location of the meningioma in the posterior cranial fossa
made it impossible to remove completely. In this situation, we
agreed that multi-variety protocols should be used. Due to
chemotherapy, her overall survival was prolonged.
Conclusions
The prognosis in NF2 is still poor. The unification of
management strategy in NF2 patients is mandatory in
providing effective treatment. Integrated, multidisciplinary
care consisting of a neurosurgeon, oncologist, otolaryngol-
ogist, neurologist, geneticist, ophthalmologist, pathologist
and radiologist is necessary.
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